• af Geijersstam, V., Kibur, M., Wang, Z., Koskela, P., Pukkala, E., Schiller, J., Lehtinen, M. and Dillner, J., Stability over time of serum antibody levels to human papillomavirus type 16. J. infect. Dis., 177, 1710-1714 (1998).
  • Bjørge, T. and 13 others, Prospective, seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. Brit. med. J., 315, 646-649 (1997).
  • Bosch, F.X., Castellsagué, X., Muñoz, N., De Sanjosé, S., Ghaffari, A.M., Gonzáles, M.G., Izarzugaza, P.V., Navarro, C., Vergara, A., Ascunte, N., Guerrero, E. and Shah, K.V., Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J. nat. Cancer Inst., 88, 1060-1067 (1996).
  • Dillner, J., Kallings, I., Brihmer, C., Sikström, B., Koskela, P., Lehtinen, M., Schiller, J.T., Sapp, M. and Mårdh, P.A., Seropositivity to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J. infect. Dis., 173, 1394-1398 (1996).
  • Dillner, J. and 14 others, Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J. nat. Cancer Inst., 89, 1293-1299 (1997).
  • Doll, R. and Peto, R., The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. nat. Cancer Inst., 66, 1191-1308 (1981).
  • Hakama, M., Lehtinen, M., Knekt, P., Aromaa, A., Leinikki, P., Miettinen, A., Paavonen, P., Peto, R. and Teppo, L., Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. Amer. J. Epidemiol., 137, 166-170 (1993).
  • Hakama, M., Magnus, K., Pettersson, F., Storm, H. and Tulinius, H., Effect of organized screening on the risk of cervical cancer in the Nordic Countries.In: A.B.Miller, J.Chamberlain, N.E.Day, M.Hakama and P.C.Prorok (eds.), UICC project on evaluation of screening for cancer, pp. 153-162, Cambridge University Press, Cambridge (1991).
  • IARC, Human papillomaviruses. IARC monographs on the evaluation of carcinogenic risks to humans. IARC Scientific Publication 64, IARC, Lyon (1995).
  • Jellum, E., Andersen, A., Lund-Larsen, P., Theodorsen, L. and Orjasjter, H., Experiences of the Janus Serum Bank in Norway. Environ. Hlth Perspect., 103 (Suppl. 3), 85-88 (1995).
  • Laurila, A., Anttila, T., Läärä, E., Bloigu, A., Virtamo, J., Albanes, D., Leinonen, M. and Saikku, P., Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer. Int. J. Cancer, 74, 31-34 (1997).
  • Lehtinen, M., Dillner, J., Knekt, P., Luostarinen, T., Aromaa, A., Kirnbauer, R., Koskela, P., Paavonen, J., Peto, R., Schiller, J.T. and Hakama, M., Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Brit. med. J., 312, 537-539 (1996).
  • Mehta, C.P., Patel, N.R. and Gray, R., Computing an exact confidence interval for the common odds ratio in several 2 × 2 contingency tables. J. Amer. Statist. Ass., 80, 969-973 (1985).
  • Paavonen, J., Stevens, C.E., Wölner-Hanssen, P., Critchlow, C.W., Derouen, T., Kiviat, N., Koutsky, L., Stamm, W.E., Corey, L. and Holmes, K.K., Colposcopic manifestations of cervical and vaginal infections. Obstet. Gynecol. Surv., 43, 373-381 (1988).
  • Parish, S., Collins, R., Peto, R., Youngman, L., Barton, J., Jayne, K., Clarke, R., Appleby, P., Lyon, V., Cederholm-Williams, S., Marshall, J. and Sleight, P., Cigarette smoking, tar yields and non-fatal myocardial infarction: 14000 cases and 32000 controls in the United Kingdom. The International Studies of Infarct Survival (ISIS) Collaborators. Brit. med. J., 311, 471-477 (1995).
  • Pisani, P., Parkin, D.M. and Ferlay, J., Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int. J. Cancer, 55, 891-903 (1993).
  • Puolakkainen, M., Vesterinen, E., Purola, E., Saikku, P. and Paavonen, J., Persistence of chlamydial antibodies after pelvic inflammatory disease. J. clin. Microbiol., 23, 924-928 (1986).
  • Rotkin, I.D., A comparison of key epidemiological studies in cervical cancer related to current searches for transmissible agents. Cancer Res., 33, 1353-1367 (1973).
  • Saikku, P. and Wang, S.-P., Chlamydia trachomatis immunotypes in Finland. Acta path. microbiol. immunol. scand. Sect. B., 95, 131-134 (1987).
  • Schachter, J., Hill, E.C., King, E.B., Heilbron, D.C., Ray, R.M., Margolis, A.J. and Greenwood, S.A., Chlamydia trachomatis and cervical neoplasia. J. Amer. med. Ass., 248, 2134-2138 (1982).
  • Scheiman, J.M. and Cutler, A.F., Helicobacter pylori and gastric cancer. Amer. J. Med., 106, 222-226 (1999).
  • Schlott, T., Ruda, G., Hoppert, M., Nagel, H., Reimer, S., Schumacher-Lütge, I.K. and Droese, M., The in situ polymerase chain reaction for detection of Chlamydia trachomatis. J. Histochem. Cytochem., 46, 1017-1023 (1998).
  • Wang, S.-P. and Grayston, J.T., Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect-immunofluorescence test. Amer. J. Ophthalmol., 70, 367-374 (1970).
  • Winkelstein, W. Jr, Smoking and cervical cancer—current status: a review. Amer. J. Epidemiol., 131, 945-957 (1990).